Anavex 2-73 (Blarcamesine)


Sigma-1 agonist + muscarinic modulator

A sigma-1 agonist with muscarinic acetylcholine receptor activity; investigated for Alzheimer disease, Parkinson dementia, and Rett syndrome.

Abstract

Anavex 2-73 (blarcamesine, AVN-101; CAS 195615-83-9; molecular formula C16H21NO; molecular weight 243.34) is a multi-target sigma-1 agonist with muscarinic acetylcholine receptor activity, developed by Anavex Life Sciences. Sigma-1 affinity is approximately 860 nM (lower than cutamesine but functionally meaningful); the compound additionally interacts with muscarinic M1 and M2 receptors. Phase 2 trials in Alzheimer disease and Parkinson disease dementia demonstrated dose-dependent improvements in some cognitive endpoints. Phase 3 in Rett syndrome (EXCELLENCE trial) reported positive results in 2024 for select endpoints. Plasma half-life is approximately 14 hours. Used as a multi-target research compound for sigma-1 and muscarinic neuropharmacology.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph